DurgicalDurgical
EN
Open the app

Pharmacology · Other glucose-lowering drugs

Pramlintide !

An injected copy of amylin, a beta-cell hormone, used with mealtime insulin. It can cause severe hypoglycemia in the hours after injection.

Updated 2026-11-01

The figure shows a pramlintide analogue peptide (San45, not pramlintide itself) bound to the human amylin 3 receptor (calcitonin receptor plus RAMP3) with its Gs protein.

Target in 3D: Amylin receptors (calcitonin receptor with RAMP proteins). PDB structure 8F2B (RCSB PDB, public domain). View the structure at RCSB PDB

Mechanism of action

Amylin is co-secreted with insulin by beta cells and is missing in type 1 diabetes and reduced in advanced type 2. Pramlintide is amylin with amino-acid changes that stop it from clumping. Acting on amylin receptors in the hindbrain, it slows gastric emptying, lowers glucagon after meals and increases satiety, so glucose rises less after eating.

  1. Activates amylin receptors in the hindbrain
  2. The stomach empties more slowly; fullness comes sooner
  3. Glucagon after meals falls
  4. Smaller glucose rise after meals

Pharmacokinetics

Absorption
Subcutaneous injection before major meals.
Elimination
Mainly by the kidney.
Half-life
Short; it acts around the meal it precedes.

Indications

Adverse effects

Common

  • Nausea (most common, mostly at the start)
  • Reduced appetite, vomiting
  • Injection-site reactions

Contraindications

  • Gastroparesis
  • Hypoglycemia unawareness or repeated severe hypoglycemia
  • Hypersensitivity to pramlintide

Key interactions

Insulin
Higher risk of severe hypoglycemia; the mealtime insulin is reduced when pramlintide starts.
Oral drugs that need fast absorption (pain relievers, antibiotics, oral contraceptives)
Slower gastric emptying delays them; they are taken well before or after the injection.

What is monitored

  • Capillary glucose before and after meals and at bedtime
  • Nausea and food intake

Administration and safety

  • Subcutaneous injection in the abdomen or thigh before major meals.
  • Never mixed with insulin in the same syringe (different pH).
  • Not given if the meal will be skipped or is very small.
  • The solution should be clear and colorless.

Nursing care

  • Before: history of gastroparesis and of severe or unnoticed hypoglycemia.
  • During: glucose checks in the hours after injection; watch for nausea.
  • Teach: recognize hypoglycemia and avoid driving or machinery until the response is known.

Pregnancy and breastfeeding

Data in pregnancy are limited; insulin alone is the usual treatment.

Test yourself

Think of the answer, then tap the question to see it.

Why is the mealtime insulin dose reduced when pramlintide is started?

Pramlintide plus insulin can cause severe hypoglycemia, especially in the first hours after injection.

Which digestive condition is a contraindication to pramlintide?

Gastroparesis, because pramlintide slows gastric emptying further.

Can pramlintide and insulin be drawn into the same syringe?

No. Their solutions have different pH and are injected separately.

Add to my cards (3)

← Back to the class: Other glucose-lowering drugs

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Pramlintide Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); Amylin 3 Receptor in complex with Gs and Pramlintide analogue peptide San45 (RCSB Protein Data Bank, 2023); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 51 (McGraw Hill, 2023); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.